Preoperative Androgen Stimulation Before Proximal Hypospadias Repair
A fourteen-month-old boy with penoscrotal hypospadias and a below-percentile glans forces a decision the pooled literature makes look easy and the severity-stratified literature makes look genuinely contested: whether preoperative androgen stimulation helps or harms a repair this proximal.
Rowan P., a fourteen-month-old boy, has penoscrotal hypospadias with moderate ventral chordee and a stretched penile length and glans width both measuring below the fifth percentile for his age — small enough that his surgeon has flagged the glans as a real technical constraint on the repair, not just a cosmetic detail. He was born at term, otherwise healthy, and his parents run a small landscaping business together that shuts down for the winter, which is part of why they specifically asked whether the surgery could happen in the next two months, while both of them can be home for his recovery.
Preoperative androgen stimulation — usually testosterone or dihydrotestosterone applied topically for six to twelve weeks before surgery — reliably increases penile length and glans width, which is not in dispute; Do and colleagues' 2023 systematic review and meta-analysis confirmed the growth effect consistently across studies. What remains genuinely contested is whether that growth translates into fewer complications or more of them, and the answer appears to depend on exactly the kind of hypospadias Rowan has. Kaya and colleagues' randomized trial of topical dihydrotestosterone gel found real benefit — glans dehiscence in 0% of treated patients versus 8% untreated, reoperation in 3% versus 24% — but that trial's population was predominantly mid-to-distal hypospadias, a milder category than his. Wu and colleagues' 2026 network meta-analysis, pooling six randomized trials and 715 patients, found androgen therapy reduced the odds of urethrocutaneous fistula overall, but the protective signal held up clearly only in mixed-severity cohorts and weakened in a sensitivity analysis restricted to distal cases; Gorduza and colleagues' series of older, more proximal, severe hypospadias repairs like Rowan's found the opposite direction — higher complication rates with hormone pretreatment, plausibly from increased postoperative edema and inflammation in already more complex repairs.
Whether the benefit that's clearest on average is the one that applies to him
I'd start topical DHT six weeks before surgery. The growth effect on penile length and glans width is consistent across every study that's measured it, and Wu and colleagues' 2026 network meta-analysis — six trials, 715 children — found androgen therapy reduced the odds of urethrocutaneous fistula overall, with an odds ratio of 0.474. A bigger glans gives the surgeon more tissue to work with, which should help regardless of severity.
The pooled result is real, and I'm not disputing the overall number. But that same meta-analysis is explicit that the protective signal held up clearly in mixed-severity cohorts and weakened once the analysis was restricted to distal cases — and several of the individual proximal-hypospadias trials that make up the “mixed” pool actually ran the other direction, with higher complication rates attributed to increased postoperative edema and inflammation.
Citing the pooled average as though it applies uniformly skips over the one stratification the field's own literature says matters most — and Rowan's repair is penoscrotal, not distal, which is exactly the subgroup where the average is least likely to describe him.
Then don't treat this as all-or-nothing on the pooled number. A shorter, lower-dose course — four weeks rather than the twelve some protocols use — could plausibly capture some real growth benefit while limiting the duration of tissue changes the proximal-hypospadias harm signal is thought to come from, and it fits the family's own timing need without either ignoring the endocrinologist's data or the urologist's severity-specific concern.
Rowan's family started a four-week course of topical DHT gel, with surgery scheduled for the end of that window to fit within the family's available recovery time.
Not agreed: whether a smaller, milder androgen course meaningfully changes the risk calculus the urologist raised, or whether it's a compromise in appearance more than substance, since neither the RCT data nor the network meta-analysis specifically tested a four-week regimen. The endocrinologist sees a shorter course as capturing most of the benefit at a fraction of the exposure; the urologist views the shortened course as untested rather than de-risked, and plans to document Rowan's outcome carefully either way.